Table 4
HBV marker profile at baseline and probable clinical staging
| HBV marker | ||||
|---|---|---|---|---|
| Clinical stage of HBV infection | HBsAg | Anti-HBs | Anti-HBc | No of subjects (%) |
| Early acute infection | Pos | Neg | Neg | 9 (3.7) |
| Either acute or chronic Infection | Pos | Pos/Neg | Pos | 9 (3.7) |
| Possibilities include: | Neg | Neg | Pos | 95 (39.0) |
| 1 HBV infection in remote past | ||||
| 2 “Low level” HBV carrier | ||||
| 3 “Window” between disappearance of HBsAg and appearance of anti-HBs | ||||
| 4 False positive reaction | ||||
| Indicates previous HBV infection and immunity to HBV infection | Neg | Pos | Pos | 111 (45.5) |
| Vaccine type response | Neg | Pos | Neg | 20 (8.2) |
| Total | 244 | |||
